Company intelligence / Profile preview

Precision Lifesciences Group

Nashville, Tennessee, United Statesclinicaltrials.ucsd.edu ↗

Ownership: Private
Development stage: Phase 3

Overview

Precision Lifesciences Group develops next-generation cancer immunotherapies. Its lead programs include patient-specific dendritic cell vaccines and engineered T-cell approaches. The most advanced asset, ICT‑107, reached a Phase 3 trial in newly diagnosed glioblastoma but was suspended. Other assets are at earlier stages or pending further development/partnerships. No recent positive pivotal clinical results have been reported.

Therapeutic areas: Oncology
Modalities: Dendritic cell-based immunotherapiesEngineered hematopoietic stem cells for T-cell generationImmune-based therapies targeting solid tumors
Industry: Biotech

Drug pipeline

1 asset

ICT-140

Discontinued

Beyond the preview

Go deeper on Precision Lifesciences Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precision Lifesciences Group.

Explore the full profile